Nuvectis Pharma, Inc. Expected to Post Q2 2024 Earnings of ($0.23) Per Share (NASDAQ:NVCT)

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Analysts at Roth Capital increased their Q2 2024 EPS estimates for shares of Nuvectis Pharma in a research report issued on Tuesday, May 7th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($0.23) for the quarter, up from their previous forecast of ($0.36). The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.52) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($0.96) EPS, FY2025 earnings at ($0.99) EPS, FY2026 earnings at ($1.02) EPS and FY2027 earnings at $1.65 EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Nuvectis Pharma in a research note on Wednesday.

Nuvectis Pharma Trading Down 0.8 %

NVCT opened at $6.38 on Friday. Nuvectis Pharma has a 12-month low of $5.92 and a 12-month high of $18.65. The firm has a market capitalization of $117.21 million, a PE ratio of -4.46 and a beta of 0.45. The firm has a 50 day moving average of $8.10 and a two-hundred day moving average of $8.20.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01).

Insider Buying and Selling

In other news, CEO Ron Bentsur acquired 5,000 shares of the firm’s stock in a transaction dated Monday, March 18th. The stock was acquired at an average cost of $10.29 per share, with a total value of $51,450.00. Following the completion of the acquisition, the chief executive officer now owns 3,242,484 shares of the company’s stock, valued at $33,365,160.36. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 38.85% of the company’s stock.

Institutional Investors Weigh In On Nuvectis Pharma

Several large investors have recently modified their holdings of the company. Strs Ohio lifted its holdings in shares of Nuvectis Pharma by 178.6% during the third quarter. Strs Ohio now owns 3,900 shares of the company’s stock worth $50,000 after purchasing an additional 2,500 shares during the period. Blue Zone Wealth Advisors LLC acquired a new stake in shares of Nuvectis Pharma during the first quarter worth $118,000. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Nuvectis Pharma during the fourth quarter worth $160,000. Finally, Baldwin Brothers LLC MA lifted its holdings in shares of Nuvectis Pharma by 22.0% during the fourth quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company’s stock worth $1,185,000 after purchasing an additional 25,660 shares during the period. 96.77% of the stock is owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.